量化癌症患者临床可操作性的不断扩大。
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer.
发表日期：2023 Oct 18
作者：
Sarah P Suehnholz, Moriah H Nissan, Hongxin Zhang, Ritika Kundra, Subhiksha Nandakumar, Calvin Lu, Stephanie Carrero, Amanda Dhaneshwar, Nicole Fernandez, Benjamin W Xu, Maria E Arcila, Ahmet Zehir, Aijazuddin Syed, A Rose Brannon, Julia E Rudolph, Eder Paraiso, Paul J Sabbatini, Ross L Levine, Ahmet Dogan, Jianjiong Gao, Marc Ladanyi, Alexander Drilon, Michael F Berger, David B Solit, Nikolaus Schultz, Debyani Chakravarty
来源：
Cancer Discovery
摘要：
关于从精准肿瘤学中受益的癌症患者比例一直存在争论，部分原因是对于哪些分子改变在临床上可行的观点存在冲突。为了量化自 2017 年以来临床可操作性的扩展，我们使用相隔 5 年部署的两个时间上不同的 OncoKB 知识库版本，对通过 MSK-IMPACT 临床测定进行测序的 47,271 个实体瘤进行了注释。 2017 年至 2022 年间，我们观察到，携带标准治疗（1 级或 2 级）治疗反应预测生物标志物的肿瘤比例从 8.9% 增加到 31.6%，携带不可操作驱动因素的肿瘤几乎减半（44.2% 到22.8%）。在临床可操作性有限或无临床可操作性的肿瘤中，TP53 (43.2%)、KRAS (19.2%) 和 CDKN2A (12.2%) 是最常改变的基因。
There is a continuing debate about the proportion of cancer patients that benefit from precision oncology, attributable in part to conflicting views as to which molecular alterations are clinically actionable. To quantify the expansion of clinical actionability since 2017, we annotated 47,271 solid tumors sequenced with the MSK-IMPACT clinical assay using two temporally distinct versions of the OncoKB knowledge base deployed 5 years apart. Between 2017 and 2022, we observed an increase from 8.9% to 31.6% in the fraction of tumors harboring a standard care (Level 1 or 2) predictive biomarker of therapy response and an almost halving of tumors carrying non-actionable drivers (44.2% to 22.8%). In tumors with limited or no clinical actionability, TP53 (43.2%), KRAS (19.2%) and CDKN2A (12.2%) were the most frequently altered genes.